Viking Therapeutics, Inc. (VKTX): Q2 2026 13F — more filers, higher aggregate reported value, and large Vanguard-affiliated / State Street adds
You are looking at Viking Therapeutics, Inc. — health care name listed on NASDAQ as VKTX. Below is a read of the latest Form 13F tape (period of report 2026-06-30, Q2 2026) versus the prior quarter (2026-03-31, Q1 2026), plus a short company overview.
Viking Therapeutics, Inc. / VIKING THERAPEUTICS INC
What changed in Q2 2026?
Last quarter = Q2 2026 (period of report 2026-06-30) versus prior Q1 2026 (2026-03-31). Figures are reported 13F values (USD) as filed — delayed snapshots, not live prices.
Here is the story in one breath: more 13F filers (433 vs 399), and the aggregate reported 13F value rose (about $2.93B from about $2.07B). Total disclosed shares also moved to about 75,747,985 from about 62,717,183. Hedge-style* holders numbered 0 in Q2 2026 versus 1 in Q1 2026. On the full 13F tape, 89 managers entered and 55 exited (hedge-style* enter/exit: 0 / 1).
Status mix across the QoQ tape (488 manager rows including exits): 89 ENTERED, 55 EXITED, 136 INCREASED, 128 DECREASED, 80 UNCHANGED.
Reporting-entity note: several Vanguard-affiliated names appear as ENTERED under new CIKs in Q2 2026 (for example VANGUARD CAPITAL MANAGEMENT LLC ($197.14M), VANGUARD PORTFOLIO MANAGEMENT LLC ($174.93M), VANGUARD FIDUCIARY TRUST CO ($28.56M), VANGUARD ASSET MANAGEMENT, Ltd ($4.27M)). That is a 13F filer / CIK event in this tape — not automatically the same thing as “Vanguard never owned VKTX before.” Read it as new reporting entities showing up for this CUSIP in the QoQ join.
Who holds VKTX now?
Largest Q2 2026 13F holders by reported position value (top 18 of 433). Block size ≈ reported value. Click a name for the fund page.
Fund activity — Q1 2026 → Q2 2026
Top increases and decreases by change in % of the manager’s reported AUM, shown as treemap-style cards. Dollar heatmaps follow.
Top funds increasing % AUM
Largest positive Δ %AUM (entries + any adds).
Top funds decreasing % AUM
Largest negative Δ %AUM (cuts + exits).
Top $ increases (reported value)
Top $ decreases (reported value)
Funds entering & exiting
New fund appearances (ENTERED) and disappearances (EXITED) on the QoQ 13F tape — all filers vs hedge-style* only. Counts are status rows from the QoQ join across the full Form 13F filer set for this CUSIP/ticker — not live flow.
Key Q2 2026 movers (by |Δ reported value|)
The largest absolute dollar increase is VANGUARD CAPITAL MANAGEMENT LLC (status ENTERED, Δ about $197.14M) — accession 0002100119-26-001527. On the downside, the largest absolute dollar decrease is RAYMOND JAMES FINANCIAL INC (DECREASED, Δ about -$82.51M).
Classic 13F reminder: BlackRock, Inc. cut shares (6,880,290 → 6,189,649) but still shows a higher reported value ($223.88M → $241.46M) — share cuts and dollar increases can sit in the same row when the filing-period price jumps.
Largest Q2 2026 ENTERED names by reported value include: VANGUARD CAPITAL MANAGEMENT LLC ($197.14M), VANGUARD PORTFOLIO MANAGEMENT L… ($174.93M), VANGUARD FIDUCIARY TRUST CO ($28.56M), Jump Financial, LLC ($22.62M), Point72 Asset Management, L.P. ($18.46M).
Largest EXITED names by prior reported value include: VOLORIDGE INVESTMENT MANAGEMENT… (prior $11.67M), Integral Health Asset Managemen… (prior $8.13M), SCHRODER INVESTMENT MANAGEMENT … (prior $5.50M), 683 Capital Management, LLC (prior $4.23M), BAMCO INC /NY/ (prior $4.08M).
Top QoQ activity rows (by |Δ value|)
Showing 50 of 488 QoQ manager rows — sorted by absolute change in reported value.
| Manager | Status | Shares Q1 | Shares Q2 | Value Q1 | Value Q2 | Δ Value | SEC |
|---|---|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ENTERED | — | 5,053,663 | — | $197.14M | $197.14M | SEC |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ENTERED | — | 4,484,263 | — | $174.93M | $174.93M | SEC |
| RAYMOND JAMES FINANCIAL INC | DECREASED | 2,075,403 | 794,660 | $113.51M | $31.00M | -$82.51M | SEC |
| STATE STREET CORP | INCREASED | 4,395,557 | 5,606,394 | $143.03M | $218.71M | $75.67M | SEC |
| FMR LLC | INCREASED | 6,024,753 | 6,335,756 | $196.05M | $247.16M | $51.11M | SEC |
| MORGAN STANLEY | INCREASED | 3,013,928 | 3,486,040 | $98.07M | $135.99M | $37.92M | SEC |
| AMERIPRISE FINANCIAL INC | INCREASED | 1,678,745 | 2,156,083 | $54.63M | $84.11M | $29.48M | SEC |
| VANGUARD FIDUCIARY TRUST CO | ENTERED | — | 732,047 | — | $28.56M | $28.56M | SEC |
| Jump Financial, LLC | ENTERED | — | 579,882 | — | $22.62M | $22.62M | SEC |
| JPMORGAN CHASE & CO | INCREASED | 485,703 | 915,185 | $14.53M | $36.39M | $21.86M | SEC |
| BNP PARIBAS FINANCIAL MARKETS | INCREASED | 540,499 | 981,700 | $17.59M | $38.30M | $20.71M | SEC |
| Point72 Asset Management, L.P. | ENTERED | — | 473,308 | — | $18.46M | $18.46M | SEC |
| BlackRock, Inc. | DECREASED | 6,880,290 | 6,189,649 | $223.88M | $241.46M | $17.57M | SEC |
| Eversept Partners, LP | INCREASED | 239,110 | 602,922 | $7.78M | $23.52M | $15.74M | SEC |
| ADAR1 Capital Management, LLC | INCREASED | 227,717 | 574,038 | $7.41M | $22.39M | $14.98M | SEC |
| GEODE CAPITAL MANAGEMENT, LLC | INCREASED | 2,082,067 | 2,097,981 | $67.77M | $81.87M | $14.10M | SEC |
| ExodusPoint Capital Management, LP | ENTERED | — | 361,126 | — | $14.09M | $14.09M | SEC |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | EXITED | 358,660 | — | $11.67M | — | -$11.67M | SEC |
| MILLENNIUM MANAGEMENT LLC | INCREASED | 250,525 | 498,172 | $8.15M | $19.43M | $11.28M | SEC |
| JANE STREET GROUP, LLC | INCREASED | 748,949 | 899,558 | $24.37M | $35.09M | $10.72M | SEC |
| Timothy G. Youngquist 2020 Irrevocable Trust | ENTERED | — | 271,849 | — | $10.60M | $10.60M | SEC |
| TWO SIGMA INVESTMENTS, LP | DECREASED | 4,432,142 | 3,937,414 | $144.22M | $153.60M | $9.38M | SEC |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | INCREASED | 705,809 | 816,367 | $22.97M | $31.85M | $8.88M | SEC |
| Integral Health Asset Management, LLC | EXITED | 250,000 | — | $8.13M | — | -$8.13M | SEC |
| D. E. Shaw & Co., Inc. | DECREASED | 1,676,713 | 1,605,994 | $54.56M | $62.65M | $8.09M | SEC |
| CITIGROUP INC | INCREASED | 109,295 | 293,126 | $3.56M | $11.43M | $7.88M | SEC |
| AQR CAPITAL MANAGEMENT LLC | INCREASED | 12,172 | 200,958 | $390,000 | $7.84M | $7.45M | SEC |
| UBS Group AG | DECREASED | 1,347,472 | 936,055 | $43.85M | $36.52M | -$7.33M | SEC |
| KORNITZER CAPITAL MANAGEMENT INC /KS | ENTERED | — | 155,662 | — | $6.07M | $6.07M | SEC |
| NORTHERN TRUST CORP | INCREASED | 573,276 | 626,719 | $18.65M | $24.45M | $5.79M | SEC |
| GOLDMAN SACHS GROUP INC | DECREASED | 960,570 | 942,841 | $31.26M | $36.78M | $5.52M | SEC |
| SCHRODER INVESTMENT MANAGEMENT GROUP | EXITED | 183,846 | — | $5.50M | — | -$5.50M | SEC |
| TUDOR INVESTMENT CORP ET AL | INCREASED | 70,789 | 197,331 | $2.30M | $7.70M | $5.39M | SEC |
| Granahan Investment Management, LLC | DECREASED | 332,192 | 148,044 | $10.81M | $5.78M | -$5.03M | SEC |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DECREASED | 736,465 | 730,690 | $23.96M | $28.50M | $4.54M | SEC |
| Man Group plc | INCREASED | 239,263 | 312,171 | $7.79M | $12.18M | $4.39M | SEC |
| VANGUARD ASSET MANAGEMENT, Ltd | ENTERED | — | 109,560 | — | $4.27M | $4.27M | SEC |
| 683 Capital Management, LLC | EXITED | 130,000 | — | $4.23M | — | -$4.23M | SEC |
| BANK OF AMERICA CORP /DE/ | INCREASED | 330,720 | 383,775 | $10.76M | $14.97M | $4.21M | SEC |
| BLAIR WILLIAM & CO/IL | INCREASED | 371,119 | 416,766 | $12.08M | $16.26M | $4.18M | SEC |
| BAMCO INC /NY/ | EXITED | 125,486 | — | $4.08M | — | -$4.08M | SEC |
| Pictet Asset Management Holding SA | DECREASED | 696,301 | 682,909 | $22.66M | $26.64M | $3.98M | SEC |
| CITADEL ADVISORS LLC | DECREASED | 1,262,221 | 951,515 | $41.07M | $37.12M | -$3.95M | SEC |
| Connor, Clark & Lunn Investment Management Ltd. | INCREASED | 516,108 | 530,607 | $16.79M | $20.70M | $3.90M | SEC |
| LBP AM SA | ENTERED | — | 93,906 | — | $3.66M | $3.66M | SEC |
| Trexquant Investment LP | INCREASED | 22,728 | 112,499 | $739,569 | $4.39M | $3.65M | SEC |
| WORLDQUANT MILLENNIUM ADVISORS LLC | ENTERED | — | 91,634 | — | $3.57M | $3.57M | SEC |
| ROYAL BANK OF CANADA | DECREASED | 397,968 | 241,032 | $12.95M | $9.40M | -$3.55M | SEC |
| WINTON GROUP Ltd | ENTERED | — | 90,546 | — | $3.53M | $3.53M | SEC |
| DIMENSIONAL FUND ADVISORS LP | DECREASED | 542,516 | 540,053 | $17.65M | $21.07M | $3.41M | SEC |
Company AI overview — Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders. Common stock trades on NASDAQ as VKTX. HQ: 9920 Pacific Heights Blvd, Suite 500, San Diego, California 92121. Sources: ir.vikingtherapeutics.com; vikingtherapeutics.com; SEC CIK 0001607678.
Short history / footprint. Viking develops product candidates aimed at metabolic diseases (including obesity-related programs highlighted in company materials). As a clinical-stage issuer, value creation is pipeline- and trial-driven rather than commercial-product-driven today.
Business model & revenue streams. Near-term economics are R&D / clinical development funded by capital markets and partnerships as disclosed — not large commercial product sales. Milestone and collaboration economics, if any, appear in SEC filings.
Competition. Other obesity / metabolic biotechs and large pharma GLP-1 / related franchises compete for patients, KOLs, and partnership attention. Trial design, safety, convenience (oral vs injectable), and manufacturing scale matter.
Moat (humble take). Clinical data and IP can create optionality — still binary trial and regulatory risk. Treat “moat” language carefully for clinical-stage names.
Challenges & opportunities. Challenges: clinical execution, financing, and competitive obesity pipelines. Opportunities: positive trial readouts, partnering, and addressing large metabolic indications if approved.
Recent update (company IR). Check ir.vikingtherapeutics.com for earnings dates and pipeline updates, and SEC Forms 10-K / 10-Q for cash runway and trial status. Prefer issuer / EDGAR sources over secondary summaries.
Q2 2026 accession sample (largest holders)
SEC index links for accessions tied to the largest Q2 2026 reported positions. Filing dates live on each EDGAR index page.
| Accession | Manager | CIK | Type |
|---|---|---|---|
| 0000315066-26-002260 | FMR LLC | 315066 | 13F-HR |
| 0002012383-26-003238 | BlackRock, Inc. | 2012383 | 13F-HR |
| 0000093751-26-000507 | STATE STREET CORP | 93751 | 13F-HR |
| 0002100119-26-001527 | VANGUARD CAPITAL MANAGEMENT LLC | 2100119 | 13F-HR |
| 0002100121-26-001018 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2100121 | 13F-HR |
| 0000899140-26-000855 | TWO SIGMA INVESTMENTS, LP | 1179392 | 13F-HR |
| 0000895421-26-000243 | MORGAN STANLEY | 895421 | 13F-HR |
| 0001193125-26-351426 | AMERIPRISE FINANCIAL INC | 820027 | 13F-HR |
| 0001214717-26-000008 | GEODE CAPITAL MANAGEMENT, LLC | 1214717 | 13F-HR |
| 0000748054-26-000005 | AMERICAN CENTURY COMPANIES INC | 748054 | 13F-HR |
| 0001104659-26-097217 | D. E. Shaw & Co., Inc. | 1009207 | 13F-HR |
| 0001166588-26-000008 | BNP PARIBAS FINANCIAL MARKETS | 1166588 | 13F-HR |
| 0001104659-26-097200 | CITADEL ADVISORS LLC | 1423053 | 13F-HR |
| 0000886982-26-000519 | GOLDMAN SACHS GROUP INC | 886982 | 13F-HR |
| 0001610520-26-000103 | UBS Group AG | 1610520 | 13F-HR |
Sources & provenance
- Company site: https://vikingtherapeutics.com/
- Investor relations: https://ir.vikingtherapeutics.com/
- About / overview: https://vikingtherapeutics.com/
- Form 13F holdings for period of report 2026-06-30 and 2026-03-31 — individual SEC accession index links in the tables above (EDGAR pattern
https://www.sec.gov/Archives/edgar/data/{cik_from_accession}/{accession_nodash}/{accession}-index.htm). - QuantyFight stock page: https://quantyfight.com/stocks/VKTX
- Market-cap context on this page ≈ $3.8B from holdings metadata (rounded).
More stock research
Open the live VKTX page · Fund research · Quarterly insights